Back to top
more

Perrigo (PRGO)

(Delayed Data from NYSE)

$27.58 USD

27.58
3,889,579

-0.60 (-2.13%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $27.57 -0.01 (-0.04%) 6:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Here's Why Perrigo (PRGO) Could be Great Choice for a Bottom Fisher

After losing some value lately, a hammer chart pattern has been formed for Perrigo (PRGO), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Are These Medical Stocks a Great Value Stocks Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Aurora Cannabis Inc. (ACB) Reports Q2 Loss, Tops Revenue Estimates

Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of -147.06% and 4.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Envista (NVST) Beats Q4 Earnings and Revenue Estimates

Envista (NVST) delivered earnings and revenue surprises of 9.52% and 2.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

Sector ETF report for XPH

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Smart Beta ETF report for XPH

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

Sector ETF report for XPH

Is SPDRSP PHARMA (XPH) a Strong ETF Right Now?

Smart Beta ETF report for XPH

Perrigo (PRGO) Misses on Q3 Earnings, Lowers Earnings View

Perrigo (PRGO) reports dismal third-quarter 2021 results. Stock declines.

Perrigo (PRGO) Q3 Earnings and Revenues Lag Estimates

Perrigo (PRGO) delivered earnings and revenue surprises of -30.77% and -0.84%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Perrigo (PRGO) This Earnings Season?

Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Earnings Preview: Perrigo (PRGO) Q3 Earnings Expected to Decline

Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Perrigo (PRGO) Stock Up on Irish Tax Bill Settlement Deal

Perrigo (PRGO) agrees to pay an aggregate of approximately $345 million (Euro 297 million) to settle its tax liability notice from the Irish Office of the Revenue Commissioners issued in 2018.

Why Is Perrigo (PRGO) Up 7.1% Since Last Earnings Report?

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Perrigo (PRGO) to Acquire Another Self-Care Company HRA Pharma

Perrigo (PRGO) offers to acquire HRA Pharma with several leading OTC brands in its portfolio for almost $2.1 billion. The acquisition will complete Perrigo's transformation into a leading self-care company.

Perrigo (PRGO) Q2 Earnings Lag, Sales Hurt by Weak Cold Season

Perrigo (PRGO) reports dismal second-quarter 2021 results. Stock down.

Perrigo (PRGO) Q2 Earnings and Revenues Lag Estimates

Perrigo (PRGO) delivered earnings and revenue surprises of -18.03% and -3.44%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Perrigo (PRGO) to Report a Decline in Earnings: What to Look Out for

Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for Perrigo (PRGO) This Earnings Season?

Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Perrigo (PRGO) Up 2.9% Since Last Earnings Report: Can It Continue?

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Perrigo (PRGO) Q1 Earnings Miss Estimates, Revenues In Line

Perrigo (PRGO) reports dismal first-quarter 2021 results. The COVID-19 pandemic continues to hurt the company's top line.

Perrigo (PRGO) Q1 Earnings and Revenues Miss Estimates

Perrigo (PRGO) delivered earnings and revenue surprises of -10.71% and -0.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Perrigo (PRGO) This Earnings Season?

Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Earnings Preview: Perrigo (PRGO) Q1 Earnings Expected to Decline

Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Perrigo (PRGO) Misses on Q4 Earnings, to Sell Generic Unit

Perrigo (PRGO) reports dismal fourth-quarter 2020 results. The company signs deal to sell its generic drug business for $1.55 billion. Stock up.